Immunotherapy in Renal Cell Carcinoma

Jennifer Cudris, Jaime R Merchan

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Renal cell carcinoma (RCC) is a chemotherapy-resistant disease, and current molecularly targeted therapies offer limited clinical benefi t but no cures. The observation that RCC is immunogenic led to immune-based strategies for the treatment of this disease. Immunotherapy with high-dose IL-2 can induce long- term, complete responses in a small percentage of patients. IFN has been used as an immune intervention as well but with much less success than IL-2. Currently IFN is used only in combination with the anti-VEGF monoclonal antibody bevacizumab. Further investigation of novel immune interventions in RCC is ongoing with promising results. Dendritic cell vaccines have been tested in single-arm clinical trials suggesting improved survival when added to standard anti-angiogenic therapy. Monoclonal antibodies against PD-1 and PD-L1, novel immune targets, have shown promising response in phase I trials. Peptide vaccines have shown effi cacy in phase II trials as well. Phase III trials to test these immune interventions are currently ongoing and have the potential to bring new, effective treatment options for patients with advanced RCC.

Original languageEnglish (US)
Title of host publicationAdvances in Tumor Immunology and Immunotherapy
PublisherSpringer New York
Pages125-147
Number of pages23
ISBN (Electronic)9781461488095
ISBN (Print)9781461488088
DOIs
StatePublished - Jan 1 2014

Fingerprint

Renal Cell Carcinoma
Immunotherapy
Interleukin-2
Monoclonal Antibodies
Subunit Vaccines
Therapeutics
Dendritic Cells
Vascular Endothelial Growth Factor A
Vaccines
Clinical Trials
Drug Therapy
Survival

Keywords

  • Clinical trials
  • IL-2
  • Immunotherapy
  • Renal Cell Carcinoma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cudris, J., & Merchan, J. R. (2014). Immunotherapy in Renal Cell Carcinoma. In Advances in Tumor Immunology and Immunotherapy (pp. 125-147). Springer New York. https://doi.org/10.1007/978-1-4614-8809-5_8

Immunotherapy in Renal Cell Carcinoma. / Cudris, Jennifer; Merchan, Jaime R.

Advances in Tumor Immunology and Immunotherapy. Springer New York, 2014. p. 125-147.

Research output: Chapter in Book/Report/Conference proceedingChapter

Cudris, J & Merchan, JR 2014, Immunotherapy in Renal Cell Carcinoma. in Advances in Tumor Immunology and Immunotherapy. Springer New York, pp. 125-147. https://doi.org/10.1007/978-1-4614-8809-5_8
Cudris J, Merchan JR. Immunotherapy in Renal Cell Carcinoma. In Advances in Tumor Immunology and Immunotherapy. Springer New York. 2014. p. 125-147 https://doi.org/10.1007/978-1-4614-8809-5_8
Cudris, Jennifer ; Merchan, Jaime R. / Immunotherapy in Renal Cell Carcinoma. Advances in Tumor Immunology and Immunotherapy. Springer New York, 2014. pp. 125-147
@inbook{a403ee20b99741a7a53a69200ed328ac,
title = "Immunotherapy in Renal Cell Carcinoma",
abstract = "Renal cell carcinoma (RCC) is a chemotherapy-resistant disease, and current molecularly targeted therapies offer limited clinical benefi t but no cures. The observation that RCC is immunogenic led to immune-based strategies for the treatment of this disease. Immunotherapy with high-dose IL-2 can induce long- term, complete responses in a small percentage of patients. IFN has been used as an immune intervention as well but with much less success than IL-2. Currently IFN is used only in combination with the anti-VEGF monoclonal antibody bevacizumab. Further investigation of novel immune interventions in RCC is ongoing with promising results. Dendritic cell vaccines have been tested in single-arm clinical trials suggesting improved survival when added to standard anti-angiogenic therapy. Monoclonal antibodies against PD-1 and PD-L1, novel immune targets, have shown promising response in phase I trials. Peptide vaccines have shown effi cacy in phase II trials as well. Phase III trials to test these immune interventions are currently ongoing and have the potential to bring new, effective treatment options for patients with advanced RCC.",
keywords = "Clinical trials, IL-2, Immunotherapy, Renal Cell Carcinoma",
author = "Jennifer Cudris and Merchan, {Jaime R}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-8809-5_8",
language = "English (US)",
isbn = "9781461488088",
pages = "125--147",
booktitle = "Advances in Tumor Immunology and Immunotherapy",
publisher = "Springer New York",

}

TY - CHAP

T1 - Immunotherapy in Renal Cell Carcinoma

AU - Cudris, Jennifer

AU - Merchan, Jaime R

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Renal cell carcinoma (RCC) is a chemotherapy-resistant disease, and current molecularly targeted therapies offer limited clinical benefi t but no cures. The observation that RCC is immunogenic led to immune-based strategies for the treatment of this disease. Immunotherapy with high-dose IL-2 can induce long- term, complete responses in a small percentage of patients. IFN has been used as an immune intervention as well but with much less success than IL-2. Currently IFN is used only in combination with the anti-VEGF monoclonal antibody bevacizumab. Further investigation of novel immune interventions in RCC is ongoing with promising results. Dendritic cell vaccines have been tested in single-arm clinical trials suggesting improved survival when added to standard anti-angiogenic therapy. Monoclonal antibodies against PD-1 and PD-L1, novel immune targets, have shown promising response in phase I trials. Peptide vaccines have shown effi cacy in phase II trials as well. Phase III trials to test these immune interventions are currently ongoing and have the potential to bring new, effective treatment options for patients with advanced RCC.

AB - Renal cell carcinoma (RCC) is a chemotherapy-resistant disease, and current molecularly targeted therapies offer limited clinical benefi t but no cures. The observation that RCC is immunogenic led to immune-based strategies for the treatment of this disease. Immunotherapy with high-dose IL-2 can induce long- term, complete responses in a small percentage of patients. IFN has been used as an immune intervention as well but with much less success than IL-2. Currently IFN is used only in combination with the anti-VEGF monoclonal antibody bevacizumab. Further investigation of novel immune interventions in RCC is ongoing with promising results. Dendritic cell vaccines have been tested in single-arm clinical trials suggesting improved survival when added to standard anti-angiogenic therapy. Monoclonal antibodies against PD-1 and PD-L1, novel immune targets, have shown promising response in phase I trials. Peptide vaccines have shown effi cacy in phase II trials as well. Phase III trials to test these immune interventions are currently ongoing and have the potential to bring new, effective treatment options for patients with advanced RCC.

KW - Clinical trials

KW - IL-2

KW - Immunotherapy

KW - Renal Cell Carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85028513981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028513981&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-8809-5_8

DO - 10.1007/978-1-4614-8809-5_8

M3 - Chapter

SN - 9781461488088

SP - 125

EP - 147

BT - Advances in Tumor Immunology and Immunotherapy

PB - Springer New York

ER -